人类巨细胞病毒血清阳性与脓毒症患者生存率降低相关
该研究基于多中心SepsisDataNet.NRW研究前瞻性纳入410例按SEPSIS-3标准诊断的脓毒症患者,检测HCMV血清状态(潜伏),并在入组后第1、4、8天定量13种细胞因子,对171例患者血浆行蛋白质组学分析。结果显示HCMV血清阳性患者30天死亡率高于血清阴性患者(38% vs 25%,p=0.008;HR 1.656,95%CI 1.135-2.417),校正年龄后仍独立相关(p=0.010;HR 1.673,95%CI 1.131-2.477)。IL-6升高的预测价值仅见于血清阳性队列(30天死亡率63% vs 24%;HR 3.250,95%CI 2.075-5.090;p<0.001),而两组间IL-6血清浓度无显著差异;降钙素原和IL-10表现相同,仅在HCMV血清阳性患者中预测结局。作者建议结合HCMV血清状态重新评估炎症相关生物标志物的预测价值。
要点
- 多中心前瞻性观察:HCMV血清阳性脓毒症患者30天死亡率38%,高于血清阴性者的25%(p=0.008;HR 1.656,95%CI 1.135-2.417)。
- 校正年龄后HCMV血清阳性与30天死亡率的关联仍独立存在(p=0.010;HR 1.673,95%CI 1.131-2.477)。
- IL-6升高的预后预测价值仅见于HCMV血清阳性队列(30天死亡率63% vs 24%;HR 3.250,95%CI 2.075-5.090;p<0.001),两组间IL-6血清浓度无显著差异。
- 降钙素原和IL-10表现相同,仅在HCMV血清阳性患者中预测结局。
- 作者建议结合HCMV血清状态重新评估炎症相关生物标志物的预测价值,并认为靶向HCMV潜伏可能为脓毒症个体化治疗筛选合适患者提供新思路。
适用人群与场景
- 多中心SepsisDataNet.NRW研究前瞻性纳入的410例脓毒症患者,按SEPSIS-3标准诊断。
- 血浆蛋白质组学分析来自其中171例患者的血浆样本。
诊断标准与关键阈值
- 脓毒症诊断依据SEPSIS-3标准。
- HCMV血清状态(即潜伏状态)为分组依据。
研究设计与关键结果
- 研究类型:多中心前瞻性观察性研究,纳入410例脓毒症患者,检测HCMV血清状态,入组后第1、4、8天定量13种细胞因子,并对171例患者血浆行蛋白质组学分析。
- 主要终点:HCMV血清阳性患者30天死亡率38%,血清阴性患者25%(p=0.008;HR 1.656,95%CI 1.135-2.417)。
- 校正年龄后HCMV血清阳性与30天死亡率仍独立相关(p=0.010;HR 1.673,95%CI 1.131-2.477)。
- IL-6升高的预测价值仅见于HCMV血清阳性队列(30天死亡率63% vs 24%;HR 3.250,95%CI 2.075-5.090;p<0.001),两组间IL-6血清浓度无显著差异。
- 降钙素原和IL-10表现相同,仅在HCMV血清阳性患者中预测结局。
证据类型、等级与局限
- 证据类型:多中心前瞻性观察性研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者建议结合HCMV血清状态重新评估炎症相关生物标志物(如IL-6、降钙素原、IL-10)的预测价值。
- 作者认为靶向HCMV潜伏可能为脓毒症个体化治疗筛选合适患者提供新思路。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Sepsis is one of the leading causes of death. Treatment attempts targeting the immune response regularly fail in clinical trials. As HCMV latency can modulate the immune response and changes the immune cell composition, we hypothesized that HCMV serostatus affects mortality in sepsis patients.
METHODS: We determined the HCMV serostatus (i.e., latency) of 410 prospectively enrolled patients of the multicenter SepsisDataNet.NRW study. Patients were recruited according to the SEPSIS-3 criteria and clinical data were recorded in an observational approach. We quantified 13 cytokines at Days 1, 4, and 8 after enrollment. Proteomics data were analyzed from the plasma samples of 171 patients.
RESULTS: The 30-day mortality was higher in HCMV-seropositive patients than in seronegative sepsis patients (38% vs. 25%, respectively; p = 0.008; HR, 1.656; 95% CI 1.135-2.417). This effect was observed independent of age (p = 0.010; HR, 1.673; 95% CI 1.131-2.477). The predictive value on the outcome of the increased concentrations of IL-6 was present only in the seropositive cohort (30-day mortality, 63% vs. 24%; HR 3.250; 95% CI 2.075-5.090; p < 0.001) with no significant differences in serum concentrations of IL-6 between the two groups. Procalcitonin and IL-10 exhibited the same behavior and were predictive of the outcome only in HCMV-seropositive patients.
CONCLUSION: We suggest that the predictive value of inflammation-associated biomarkers should be re-evaluated with regard to the HCMV serostatus. Targeting HCMV latency might open a new approach to selecting suitable patients for individualized treatment in sepsis.
参考来源
- Unterberg M, Ehrentraut SF, Bracht T, et al. Human cytomegalovirus seropositivity is associated with reduced patient survival during sepsis. Crit Care. 2023. PMID: 37907989. doi:10.1186/s13054-023-04713-1
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。